US20220162667A1 - Systems for protein-protein interaction screening - Google Patents

Systems for protein-protein interaction screening Download PDF

Info

Publication number
US20220162667A1
US20220162667A1 US17/299,728 US201917299728A US2022162667A1 US 20220162667 A1 US20220162667 A1 US 20220162667A1 US 201917299728 A US201917299728 A US 201917299728A US 2022162667 A1 US2022162667 A1 US 2022162667A1
Authority
US
United States
Prior art keywords
polypeptide
certain embodiments
nucleic acid
fragment
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
US17/299,728
Other languages
English (en)
Inventor
Henry Chan
Leon Yen-Lee CHAN
Aaron Ross Cooper
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Octant Inc
Original Assignee
Octant Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Octant Inc filed Critical Octant Inc
Priority to US17/299,728 priority Critical patent/US20220162667A1/en
Assigned to OCTANT, INC. reassignment OCTANT, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CHAN, HENRY, CHAN, Leon Yen-Lee, COOPER, AARON ROSS
Publication of US20220162667A1 publication Critical patent/US20220162667A1/en
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1055—Protein x Protein interaction, e.g. two hybrid selection
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B06—GENERATING OR TRANSMITTING MECHANICAL VIBRATIONS IN GENERAL
    • B06B—METHODS OR APPARATUS FOR GENERATING OR TRANSMITTING MECHANICAL VIBRATIONS OF INFRASONIC, SONIC, OR ULTRASONIC FREQUENCY, e.g. FOR PERFORMING MECHANICAL WORK IN GENERAL
    • B06B1/00—Methods or apparatus for generating mechanical vibrations of infrasonic, sonic, or ultrasonic frequency
    • B06B1/02—Methods or apparatus for generating mechanical vibrations of infrasonic, sonic, or ultrasonic frequency making use of electrical energy
    • B06B1/0207—Driving circuits
    • B06B1/0223—Driving circuits for generating signals continuous in time
    • B06B1/0269—Driving circuits for generating signals continuous in time for generating multiple frequencies
    • B06B1/0276—Driving circuits for generating signals continuous in time for generating multiple frequencies with simultaneous generation, e.g. with modulation, harmonics
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B06—GENERATING OR TRANSMITTING MECHANICAL VIBRATIONS IN GENERAL
    • B06B—METHODS OR APPARATUS FOR GENERATING OR TRANSMITTING MECHANICAL VIBRATIONS OF INFRASONIC, SONIC, OR ULTRASONIC FREQUENCY, e.g. FOR PERFORMING MECHANICAL WORK IN GENERAL
    • B06B1/00—Methods or apparatus for generating mechanical vibrations of infrasonic, sonic, or ultrasonic frequency
    • B06B1/02—Methods or apparatus for generating mechanical vibrations of infrasonic, sonic, or ultrasonic frequency making use of electrical energy
    • B06B1/0292—Electrostatic transducers, e.g. electret-type
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06V—IMAGE OR VIDEO RECOGNITION OR UNDERSTANDING
    • G06V40/00—Recognition of biometric, human-related or animal-related patterns in image or video data
    • G06V40/10—Human or animal bodies, e.g. vehicle occupants or pedestrians; Body parts, e.g. hands
    • G06V40/12—Fingerprints or palmprints
    • G06V40/13—Sensors therefor
    • G06V40/1306—Sensors therefor non-optical, e.g. ultrasonic or capacitive sensing
    • H—ELECTRICITY
    • H10—SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10K—ORGANIC ELECTRIC SOLID-STATE DEVICES
    • H10K59/00—Integrated devices, or assemblies of multiple devices, comprising at least one organic light-emitting element covered by group H10K50/00
    • H10K59/60—OLEDs integrated with inorganic light-sensitive elements, e.g. with inorganic solar cells or inorganic photodiodes
    • H10K59/65—OLEDs integrated with inorganic image sensors
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B06—GENERATING OR TRANSMITTING MECHANICAL VIBRATIONS IN GENERAL
    • B06B—METHODS OR APPARATUS FOR GENERATING OR TRANSMITTING MECHANICAL VIBRATIONS OF INFRASONIC, SONIC, OR ULTRASONIC FREQUENCY, e.g. FOR PERFORMING MECHANICAL WORK IN GENERAL
    • B06B2201/00—Indexing scheme associated with B06B1/0207 for details covered by B06B1/0207 but not provided for in any of its subgroups
    • B06B2201/70—Specific application
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • H—ELECTRICITY
    • H10—SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10K—ORGANIC ELECTRIC SOLID-STATE DEVICES
    • H10K59/00—Integrated devices, or assemblies of multiple devices, comprising at least one organic light-emitting element covered by group H10K50/00
    • H10K59/40—OLEDs integrated with touch screens

Definitions

  • nucleic acids, systems, and methods useful for interrogating protein-protein interactions, screening for antagonists or agonists of protein-protein interactions or discovering novel protein-protein interactions are useful for screening small-molecule or biologic agonists or antagonists of signaling pathways, such as G-protein coupled receptors, receptor tyrosine kinases, ion channels, and nuclear receptors.
  • the system comprises nucleic acids that encode: a) a bait protein fused to a non-functional fragment of an enzyme that can cleave a target sequence, or that can be cleaved by an endogenous enzyme; b) a prey protein (e.g., a test protein) fused to a non-functional fragment of an enzyme that can cleave a target sequence, or that can be cleaved by an endogenous enzyme that complements the enzyme or target sequence in a), and a transcription regulating protein; and c) a reporter gene under the control of a regulatory element that can be bound by the transcription regulating protein.
  • a bait protein fused to a non-functional fragment of an enzyme that can cleave a target sequence, or that can be cleaved by an endogenous enzyme
  • a prey protein e.g., a test protein fused to a non-functional fragment of an enzyme that can cleave a target sequence, or that can be cleaved by
  • the reporter gene comprises a unique molecular identifier (UMI), which is unique to each individual prey protein. This allows for multiplexing of an assay that can interrogate the effect any given stimulus has on bait and prey interaction.
  • UMI unique molecular identifier
  • a system for protein-protein interaction screening comprising: (a) a first nucleic acid encoding a bait polypeptide coupled to a first fragment of a ubiquitin polypeptide; (b) a second nucleic acid encoding a prey polypeptide coupled to a second fragment of a ubiquitin polypeptide and a transcription regulating polypeptide; and (c) a third nucleic acid comprising a reporter element, wherein said reporter element comprises a regulatory element, a first reporter gene and a second reporter gene, wherein said regulatory element is configured to be bound by said transcription regulating polypeptide, wherein said second reporter gene encodes an RNA sequence that is unique to said prey polypeptide; wherein said first fragment of a ubiquitin polypeptide and said second fragment of a ubiquitin polypeptide form a cleavable ubiquitin molecule when said bait polypeptide interacts with said prey polypeptide, whereupon said cleavable ubiquitin molecule
  • said first fragment of a ubiquitin polypeptide is a C-terminal fragment of a ubiquitin polypeptide
  • said second fragment of a ubiquitin polypeptide is an N-terminal fragment of a ubiquitin polypeptide.
  • said first fragment of a ubiquitin polypeptide is an N-terminal fragment of a ubiquitin polypeptide
  • said second fragment of a ubiquitin polypeptide is a C-terminal fragment of a ubiquitin polypeptide.
  • said transcription regulating polypeptide comprises a synthetic transcription factor.
  • said synthetic transcription factor comprises a fusion of a Gal4 DNA binding domain and-VPR activation domain.
  • said bait polypeptide or said prey polypeptide is a membrane bound signaling polypeptide.
  • said membrane-bound bait polypeptide or said prey polypeptide comprises a G protein coupled receptor, a receptor tyrosine kinase, or an ion channel.
  • said membrane-bound bait polypeptide or said prey polypeptide comprises a G protein coupled receptor.
  • said bait polypeptide or said prey polypeptide is an intracellular signaling polypeptide.
  • said intracellular bait polypeptide or said prey polypeptide comprises a nuclear hormone receptor.
  • said bait polypeptide or said prey polypeptide comprises an intracellular molecule that potentially interacts with said signaling polypeptide.
  • said regulatory element comprises an inducible regulatory element.
  • said inducible regulatory element comprises a Gal4 Upstream activation Sequence (Gal4 UAS).
  • said first reporter gene encodes a fluorescent protein, a luciferase protein, a beta-galactosidase, a beta-glucuronidase, a chloramphenicol acetyltransferase, or a secreted placental alkaline phosphatase.
  • said first reporter gene encodes a fluorescent protein or a luciferase protein.
  • said first nucleic acid comprises a sequence encoding a promoter-less fluorescent protein.
  • said fluorescent protein is a green fluorescent protein.
  • said first nucleic acid comprises a sequence that directs site specific integration into a genome.
  • said first nucleic acid comprises an attB sequence that directs site specific integration into a genome.
  • said second nucleic acid comprises a sequence encoding a selectable surface marker.
  • said selectable surface marker is a hemagglutinin polypeptide.
  • described herein is a cell comprising said first nucleic acid, said second nucleic acid, and/or said third nucleic acid.
  • said first nucleic acid, said second nucleic acid, and/or said third nucleic acid are integrated at an integration site for a transposable element. In certain embodiments, said first nucleic acid, said second nucleic acid, and/or said third nucleic acid are integrated at a predetermined genomic location.
  • described herein is a method for testing a test substances effect on a protein-protein interaction comprising contacting a cell or a populations of cells comprising the system described herein to said test substance. In certain embodiments, the test substance is a chemical.
  • a system for protein-protein interaction screening comprising: (a) a first nucleic acid encoding a bait polypeptide coupled to a first fragment of a protease polypeptide, a protease cleavage site, and a transcription regulating polypeptide; (b) a second nucleic acid encoding a prey polypeptide coupled to a second fragment of a protease polypeptide; and (c) a third nucleic acid comprising a reporter element, wherein said reporter element comprises a regulatory element, a first reporter gene and a second reporter gene, wherein said regulatory element is configured to be bound by said transcription regulating polypeptide, wherein said second reporter gene encodes an RNA sequence that is unique to said prey polypeptide; wherein said first fragment of a protease polypeptide and said second fragment of a protease polypeptide form an active protease when said bait polypeptide interacts with said prey polypeptide, whereupon said
  • said first fragment of a protease polypeptide is a C-terminal fragment of a protease polypeptide
  • said second fragment of a protease polypeptide is an N-terminal fragment of a protease polypeptide.
  • said first fragment of a protease polypeptide is a N-terminal fragment of a protease polypeptide
  • said second fragment of a protease polypeptide is a C-terminal fragment of a protease polypeptide.
  • said first fragment of a protease polypeptide and said second fragment of a protease polypeptide are derived from Tobacco Etch Virus nuclear-inclusion-a endopeptidase (TEV protease).
  • said transcription regulating polypeptide comprises a synthetic transcription factor.
  • said synthetic transcription factor comprises a fusion of a Gal4 DNA binding domain and-VPR activation domain.
  • said second nucleic acid encodes a second transcription regulating polypeptide coupled to said prey polypeptide, wherein said second transcription regulating polypeptide is configured to be cleaved by said active protease.
  • said bait polypeptide or said prey polypeptide is a membrane bound signaling polypeptide.
  • said membrane-bound bait polypeptide or said prey polypeptide comprises a G protein coupled receptor, a receptor tyrosine kinase, or an ion channel.
  • said membrane-bound signaling polypeptide or said prey polypeptide comprises a G protein coupled receptor.
  • said bait polypeptide or said prey polypeptide is an intracellular signaling polypeptide.
  • said intracellular bait polypeptide or said prey polypeptide comprises a nuclear hormone receptor.
  • said bait polypeptide or said prey polypeptide comprises an intracellular molecule that potentially interacts with said bait polypeptide.
  • said regulatory element comprises an inducible regulatory element.
  • said inducible regulatory element comprises a Gal4 Upstream activation Sequence (Gal4 UAS).
  • said first reporter gene encodes a fluorescent protein, a luciferase protein, a beta-galactosidase, a beta-glucuronidase, a chloramphenicol acetyltransferase, a secreted placental alkaline phosphatase.
  • said first reporter gene encodes a fluorescent protein or a luciferase protein.
  • said first nucleic acid comprises a sequence encoding a promoter-less fluorescent protein.
  • said fluorescent protein is a green fluorescent protein.
  • said first nucleic acid comprises a sequence that directs site specific integration into a genome.
  • said first nucleic acid comprises an attB sequence that directs site specific integration into a genome.
  • said second nucleic acid comprises a sequence encoding a selectable surface marker.
  • said selectable surface marker is a hemagglutinin polypeptide.
  • described herein is a cell comprising said first nucleic acid, said second nucleic acid, and/or said third nucleic acid.
  • said first nucleic acid, said second nucleic acid, and/or said third nucleic acid are integrated at an integration site for a transposable element. In certain embodiments, said first nucleic acid, said second nucleic acid, and/or said third nucleic acid are integrated at a predetermined genomic location.
  • described herein is a method for testing a test substances effect on a protein-protein interaction comprising contacting a cell or a populations of cells comprising the system described herein to said test substance. In certain embodiments, the test substance is a chemical.
  • FIG. 1A depicts a schematic of a split protease (left) or split-ubiquitin (right) protein-protein interaction system at steady state before binding of bait polypeptide (ARRB2) to a prey polypeptide (membrane-associated).
  • ARRB2 bait polypeptide
  • FIG. 1B depicts a schematic of a split protease (left) or split-ubiquitin (right) protein-protein interaction system at steady state after binding of bait polypeptide (ARRB2) to a prey polypeptide (membrane-associated).
  • ARRB2 bait polypeptide
  • FIG. 2 illustrates fold induction of a luminescent reporter split-ubiquitin compared to a dual-split-TEV system.
  • FIG. 3A depicts a dose response curve of cells using a split-ubiquitin protein-protein interaction system and treated with Xamoterol.
  • FIG. 3B depicts a dose response curve of cells using a dual-split-TEV protein-protein interaction system and treated with Xamoterol.
  • a system for protein-protein interaction screening comprising: (a) a first nucleic acid encoding a bait polypeptide or prey polypeptide coupled to a first fragment of a ubiquitin polypeptide; (b) a second nucleic acid encoding a prey polypeptide or a bait polypeptide coupled to a second fragment of a ubiquitin polypeptide, and a transcription regulating polypeptide; and (c) a third nucleic acid comprising a regulatory element, which is bound by said transcription regulating polypeptide and a reporter element; wherein said first fragment of a ubiquitin polypeptide and said second fragment of a ubiquitin polypeptide form a cleavable ubiquitin molecule when said bait polypeptide interacts with said prey polypeptide, whereupon said cleavable ubiquitin molecule is cleaved by a deubiquitinating enzyme, said transcription regulating polypeptide is released from said bait poly
  • a system for protein-protein interaction screening comprising: (a) a first nucleic acid encoding a bait polypeptide or prey polypeptide coupled to a first fragment of a ubiquitin polypeptide; and (b) a second nucleic acid encoding a prey polypeptide or a bait polypeptide coupled to a second fragment of a ubiquitin polypeptide, and a transcription regulating polypeptide and comprising a regulatory element, which is bound by said transcription regulating polypeptide and a reporter element; wherein said first fragment of a ubiquitin polypeptide and said second fragment of a ubiquitin polypeptide form a cleavable ubiquitin molecule when said bait polypeptide interacts with said prey polypeptide, whereupon said cleavable ubiquitin molecule is cleaved by a deubiquitinating enzyme, said transcription regulating polypeptide is released from said bait polypeptide, binds to said regulatory element
  • a system for protein-protein interaction screening comprising: (a) a first nucleic acid encoding a bait polypeptide or prey polypeptide coupled to a first fragment of a ubiquitin polypeptide, and comprising a regulatory element, which is bound by a transcription regulating polypeptide and a reporter element; and (b) a second nucleic acid encoding a prey polypeptide or a bait polypeptide coupled to a second fragment of a ubiquitin polypeptide, and said transcription regulating polypeptide; wherein said first fragment of a ubiquitin polypeptide and said second fragment of a ubiquitin polypeptide form a cleavable ubiquitin molecule when said bait polypeptide interacts with said prey polypeptide, whereupon said cleavable ubiquitin molecule is cleaved by a deubiquitinating enzyme, said transcription regulating polypeptide is released from said bait polypeptide, binds to said regulatory
  • a method to assay for protein-protein interaction comprising: (a) subjecting a cell to a physical or chemical stimulus, said cell comprising: (i) a first nucleic acid encoding a bait polypeptide or prey polypeptide coupled to a first fragment of a ubiquitin polypeptide; (ii) a second nucleic acid encoding a prey polypeptide or a bait polypeptide coupled to a second fragment of a ubiquitin polypeptide, and a transcription regulating polypeptide; and (iii) a third nucleic acid comprising a regulatory element, which is bound by said transcription regulating polypeptide and a reporter element; wherein said first fragment of a ubiquitin polypeptide and said second fragment of a ubiquitin polypeptide form a cleavable ubiquitin molecule when said bait polypeptide interacts with said prey polypeptide, whereupon said cleavable ubiquitin molecule is cle
  • a method to assay for protein-protein interaction comprising: (a) subjecting a cell to a physical or chemical stimulus, said cell comprising: (i) a first nucleic acid encoding a bait polypeptide or prey polypeptide coupled to a first fragment of a ubiquitin polypeptide; and (ii) a second nucleic acid encoding a prey polypeptide or a bait polypeptide coupled to a second fragment of a ubiquitin polypeptide, and a transcription regulating polypeptide, and comprising a regulatory element, which is bound by said transcription regulating polypeptide and a reporter element; wherein said first fragment of a ubiquitin polypeptide and said second fragment of a ubiquitin polypeptide form a cleavable ubiquitin molecule when said bait polypeptide interacts with said prey polypeptide, whereupon said cleavable ubiquitin molecule is cleaved by a deubiquitinating
  • a method to assay for protein-protein interaction comprising: (a) subjecting a cell to a physical or chemical stimulus, said cell comprising: (i) a first nucleic acid encoding a bait polypeptide or prey polypeptide coupled to a first fragment of a ubiquitin polypeptide, and comprising a regulatory element, which is bound by a transcription regulating polypeptide and a reporter element; and (ii) a second nucleic acid encoding a prey polypeptide or a bait polypeptide coupled to a second fragment of a ubiquitin polypeptide, and said transcription regulating polypeptide; wherein said first fragment of a ubiquitin polypeptide and said second fragment of a ubiquitin polypeptide form a cleavable ubiquitin molecule when said bait polypeptide interacts with said prey polypeptide, whereupon said cleavable ubiquitin molecule is cleaved by a deubiquitinating
  • a system for protein-protein interaction screening comprising: (a) a first nucleic acid encoding a bait polypeptide or prey polypeptide coupled to a first fragment of a protease polypeptide, a protease cleavage site, and a transcription regulating polypeptide; (b) a second nucleic acid encoding a prey polypeptide or a bait polypeptide coupled to a second fragment of a protease polypeptide; and (c) a third nucleic acid comprising a regulatory element, which is bound by said transcription regulating polypeptide and a reporter element; wherein said first fragment of a protease polypeptide and said second fragment of a protease polypeptide form an active protease when said bait polypeptide interacts with said prey polypeptide, whereupon said protease cleavage site is cleaved by said active protease, said transcription regulating polypeptide is released from said bait
  • a system for protein-protein interaction screening comprising: (a) a first nucleic acid encoding a bait polypeptide or prey polypeptide coupled to a first fragment of a protease polypeptide, a protease cleavage site, and a transcription regulating polypeptide; (b) a second nucleic acid encoding a prey polypeptide or a bait polypeptide coupled to a second fragment of a protease polypeptide, and comprising a regulatory element, which is bound by said transcription regulating polypeptide and a reporter element; wherein said first fragment of a protease polypeptide and said second fragment of a protease polypeptide form an active protease when said bait polypeptide interacts with said prey polypeptide, whereupon said protease cleavage site is cleaved by said active protease, said transcription regulating polypeptide is released from said bait polypeptide, binds to said regulatory
  • a system for protein-protein interaction screening comprising: (a) a first nucleic acid encoding a bait polypeptide or prey polypeptide coupled to a first fragment of a protease polypeptide, a protease cleavage site, and a transcription regulating polypeptide, and comprising a regulatory element, which is bound by said transcription regulating polypeptide and a reporter element; (b) a second nucleic acid encoding a prey polypeptide or a bait polypeptide coupled to a second fragment of a protease polypeptide; wherein said first fragment of a protease polypeptide and said second fragment of a protease polypeptide form an active protease when said bait polypeptide interacts with said prey polypeptide, whereupon said protease cleavage site is cleaved by said active protease, said transcription regulating polypeptide is released from said bait polypeptide, binds to said regulatory
  • a method to assay for protein-protein interaction comprising: (a) subjecting a cell to a physical or chemical stimulus, said cell comprising: (i) a first nucleic acid encoding a bait polypeptide or prey polypeptide coupled to a first fragment of a protease polypeptide, a protease cleavage site, and a transcription regulating polypeptide; (ii) a second nucleic acid encoding a prey polypeptide or a bait polypeptide coupled to a second fragment of a protease polypeptide; and (iii) a third nucleic acid comprising a regulatory element, which is bound by said transcription regulating polypeptide and a reporter element; wherein said first fragment of a protease polypeptide and said second fragment of a protease polypeptide form an active protease when said bait polypeptide interacts with said prey polypeptide, whereupon said protease cleavage site
  • a method to assay for protein-protein interaction comprising: (a) subjecting a cell to a physical or chemical stimulus, said cell comprising: (i) a first nucleic acid encoding a bait polypeptide or prey polypeptide coupled to a first fragment of a protease polypeptide, a protease cleavage site, and a transcription regulating polypeptide; (ii) a second nucleic acid encoding a prey polypeptide or a bait polypeptide coupled to a second fragment of a protease polypeptide and comprising a regulatory element, which is bound by said transcription regulating polypeptide, and a reporter element; wherein said first fragment of a protease polypeptide and said second fragment of a protease polypeptide form an active protease when said bait polypeptide interacts with said prey polypeptide, whereupon said protease cleavage site is cleaved by said active proteas
  • a method to assay for protein-protein interaction comprising: (a) subjecting a cell to a physical or chemical stimulus, said cell comprising: (i) a first nucleic acid encoding a bait polypeptide or prey polypeptide coupled to a first fragment of a protease polypeptide, a protease cleavage site, and a transcription regulating polypeptide and comprising a regulatory element, which is bound by said transcription regulating polypeptide and a reporter element; (ii) a second nucleic acid encoding a prey polypeptide or a bait polypeptide coupled to a second fragment of a protease polypeptide; wherein said first fragment of a protease polypeptide, and said second fragment of a protease polypeptide form an active protease when said bait polypeptide interacts with said prey polypeptide, whereupon said protease cleavage site is cleaved by said active proteas
  • polypeptide and “protein” are used interchangeably to refer to a polymer of amino acid residues and are not limited to a minimum length.
  • Polypeptides including the provided polypeptide chains and other peptides, e.g., linkers and binding peptides, may include amino acid residues including natural and/or non-natural amino acid residues.
  • the terms also include post-expression modifications of the polypeptide, for example, glycosylation, sialylation, acetylation, phosphorylation, and the like.
  • the polypeptides may contain modifications with respect to a native or natural sequence, as long as the protein maintains the desired activity. These modifications may be deliberate, as through site-directed mutagenesis, or may be accidental, such as through mutations of hosts which produce the proteins or errors due to PCR amplification.
  • Percent (%) sequence identity with respect to a reference polypeptide sequence is the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in the reference polypeptide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are known for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software. Appropriate parameters for aligning sequences are able to be determined, including algorithms needed to achieve maximal alignment over the full length of the sequences being compared.
  • % amino acid sequence identity values are generated using the sequence comparison computer program ALIGN-2.
  • the ALIGN-2 sequence comparison computer program was authored by Genentech, Inc., and the source code has been filed with user documentation in the U.S. Copyright Office, Washington D.C., 20559, where it is registered under U.S. Copyright Registration No. TXU510087.
  • the ALIGN-2 program is publicly available from Genentech, Inc., South San Francisco, Calif., or may be compiled from the source code.
  • the ALIGN-2 program should be compiled for use on a UNIX operating system, including digital UNIX V4.0D. All sequence comparison parameters are set by the ALIGN-2 program and do not vary.
  • the % amino acid sequence identity of a given amino acid sequence A to, with, or against a given amino acid sequence B is calculated as follows: 100 times the fraction X/Y, where X is the number of amino acid residues scored as identical matches by the sequence alignment program ALIGN-2 in that program's alignment of A and B, and where Y is the total number of amino acid residues in B.
  • the polypeptides of the systems described herein can be encoded by a nucleic acid.
  • a nucleic acid is a type of polynucleotide comprising two or more nucleotide bases.
  • the nucleic acid is a component of a vector that can be used to transfer the polypeptide encoding polynucleotide into a cell.
  • the term “vector” refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked.
  • One type of vector is a genomic integrated vector, or “integrated vector,” which can become integrated into the chromosomal DNA of the host cell.
  • vectors capable of directing the expression of genes to which they are operatively linked are referred to herein as “expression vectors.”
  • Suitable vectors comprise plasmids, bacterial artificial chromosomes, yeast artificial chromosomes, viral vectors and the like.
  • regulatory elements such as promoters, enhancers, polyadenylation signals for use in controlling transcription can be derived from mammalian, microbial, viral or insect genes. The ability to replicate in a host, usually conferred by an origin of replication, and a selection gene to facilitate recognition of transformants may additionally be incorporated.
  • Plasmid vectors can be linearized for integration into a chromosomal location. Vectors can comprise sequences that direct site-specific integration into a defined location or restricted set of sites in the genome (e.g., AttP-AttB recombination). Additionally, vectors can comprise sequences derived from transposable elements for integration.
  • transfection refers to methods that intentionally introduce an exogenous nucleic acid into a cell through a process commonly used in laboratories. Transfection can be affected by, for example, lipofection, calcium phosphate precipitation, viral transduction, or electroporation. Transfection can be either transient or stable.
  • the systems, nucleic acids, and methods described herein are useful to screen for protein-protein interactions.
  • protein-protein interactions can be measured before and after an external stimulus such as a physical or chemical stimulus, or compared to control conditions run in parallel.
  • the chemical stimulus can be an agonistic or antagonistic small molecule or biologic molecule.
  • the system is useful for screening for pharmaceutical discovery purposes.
  • the system minimally comprises nucleic acid(s) encoding a bait polypeptide, a prey polypeptide, and a reporter element.
  • the bait polypeptide comprises a first fragment of a cleavable molecule or a cleaving molecule (e.g., a protease).
  • the prey polypeptide comprises a second fragment of a cleavable molecule or a cleaving molecule.
  • the prey polypeptide is a library of a plurality of prey polypeptides each encoded by a distinct nucleic acid and paired with a distinct reporter, such as for example a unique molecular identifier.
  • Either the prey polypeptide or the bait polypeptide further comprises a transcription regulating polypeptide.
  • the transcription regulating polypeptide is released either by cleavage of a fully formed protease supplied by the system, or an endogenous protease that acts on a cleavable molecule.
  • a transcription activating polypeptide is released.
  • the released transcription activating polypeptide then activates transcription of a reporter gene under the control of a promoter able to be bound by the transcription activating polypeptide.
  • the reporter gene is unique to a certain prey polypeptide.
  • Additional optional features of the system include a second transcription regulating provided, either conjugated to the same polypeptide as the first transcription regulating polypeptide or provided on the other polypeptide.
  • the transcription regulating polypeptide is replaced with a transcriptional repressor polypeptide that can bind a repressor element that is 5′ to a constitutively active reporter element, the reporter element comprising a reporter gene and a UMI. This allows for determining a disruption of a protein-protein interaction.
  • the nucleic acids comprising this system may also comprise additional elements that allow for identification and selection of cells that have been transfected with the components of the system described herein.
  • nucleic acids encoding a bait polypeptide, a prey polypeptide, and comprising a reporter element are present on separate nucleic acid molecules, for example separate plasmids or viral vectors.
  • the reporter element is present on the same nucleic acid molecule as the bait polypeptide.
  • the reporter element is present on the same nucleic acid molecule as the prey polypeptide.
  • nucleic acid(s) encoding a bait polypeptide, a prey polypeptide, and a reporter element for use in drug discovery.
  • the method comprises contacting the nucleic acid(s) with a cell or population of cells under conditions sufficient for the nucleic acid(s) to be internalized and expressed by the cell (e.g., transfected); contacting the cell with a physical or chemical stimulus; and determining activation of the reporter element by one or more assays.
  • the method comprises contacting a cell or population of cells comprising nucleic acid(s) encoding a bait polypeptide, a prey polypeptide, and a reporter element; and determining activation of the reporter element by one or more assays.
  • FIGS. 1A and 1B depicts a single interaction in a single cell. It will be understood however that this reaction occurs many times in a single cell, and that different cells can comprise different specific prey polypeptides that are part of a library comprising at least 10 1 , 10 2 , 10 3 , 10 4 , 10 5 distinct prey polypeptides.
  • a prey polypeptide is coupled to a fragment of either a protease (TEV, left side), or ubiquitin (Ub, right side).
  • the prey polypeptide which is a library of potential interactors, comprises a complementary fragment of TEV or Ub that can functionally complement the activity of the fragment coupled to the bait.
  • the schematic shows a transmembrane bait, but this could, in certain embodiments, be a soluble cytosolic polypeptide, or one that exists associated with the membrane of an intracellular organelle.
  • the functionally reconstituted protease cleaves a protease cleavage site (TCS) to release a transcription factor (TF) that can bind a promoter that activates a reporter element through its activation domain (Gal4).
  • an endogenous deubiquitinating enzyme can cleave the fully reconstituted ubiquitin to release a transcription factor (TF) that can bind a promoter that activates a reporter element through its activation domain (Gal4).
  • TF transcription factor
  • the systems, nucleic acids, and methods described herein are useful in interrogating protein-protein interactions between a bait polypeptide and a prey polypeptide.
  • the interaction of bait or prey polypeptides may be of interest if they play a role in the pathology or etiology of a human disease. Therefore, systems that can provide multiplexed and efficient methods of testing interactions between a bait polypeptide and a prey polypeptide that interacts with the bait polypeptide have high utility.
  • the bait or prey polypeptide comprises a cell surface expressed receptor or channel protein.
  • Cell surface signaling polypeptides are proteins that are inserted or tethered to the membrane and transduce a signal that effects biological function of the cell when bound by a ligand or effected by a physical stimulus.
  • the bait polypeptide comprises a G protein-coupled receptor, a receptor tyrosine kinase, or an ion channel.
  • the bait or prey polypeptide comprises a G protein coupled receptor family member.
  • G protein-coupled receptors also known as seven-(pass)-transmembrane domain receptors, are ligand binding cell surface signaling proteins.
  • GPCRs G protein-coupled receptors
  • GEF guanine nucleotide exchange factor
  • the GPCR can then activate an associated G protein by exchanging the GDP bound to the G protein for a GTP.
  • G ⁇ s, G ⁇ i/o, G ⁇ q/11, G ⁇ 12/13 There are at least about 800 GPCRs encoded in the human genome, broadly divided into Classes A, B, and C.
  • the bait or prey polypeptide comprises a receptor tyrosine kinase family member.
  • Receptor tyrosine kinases are high-affinity cell surface receptors for many polypeptide growth factors, cytokines, and hormones. Receptor tyrosine kinases have been shown not only to be key regulators of normal cellular processes but also to have a critical role in the development and progression of many types of cancer. There are many classes of RTKs any member of which can be utilized as the bait or prey polypeptide in the systems described herein.
  • the RTK bait polypeptide comprises an RTK class I (EGF receptor family) (ErbB family); RTK class II (Insulin receptor family); RTK class III (PDGF receptor family); RTK class IV (VEGF receptors family); RTK class V (FGF receptor family); RTK class VI (CCK receptor family); RTK class VII (NGF receptor family); RTK class VIII (HGF receptor family); RTK class IX (Eph receptor family); RTK class X (AXL receptor family); RTK class XI (TIE receptor family); RTK class XII (RYK receptor family); RTK class XIII (DDR receptor family); RTK class XIV (RET receptor family); RTK class XV (ROS receptor family); RTK class XVI (LTK receptor family); RTK class XVII (ROR receptor family); RTK class XVIII (MuSK receptor family); RTK class XIX (LMR receptor); or RTK class XX (Undetermined) member.
  • RTK class I Ep
  • the bait or prey polypeptide comprises an ion channel.
  • Ion channels are pore-forming membrane proteins that allow ions to pass through the channel pore. Ion channels may be classified by gating such as voltage gating, ligand gating, cyclic nucleotide gating, mechanosensitive gating, gating by other ions (e.g., calcium), light gating, or temperature gating. Ion channels may also be classified by type of ion gated and include potassium, sodium, calcium, protons, non-selective cation, or chloride.
  • the bait or prey polypeptide comprises an intracellular signaling protein.
  • the intracellular signaling protein comprises a nuclear hormone receptor.
  • Nuclear hormone receptors are a class of intracellular proteins which are bound by small-molecule ligands and interact with other proteins to initiate transcription in the nucleus. Nuclear hormone receptors can exist in the cytosol associated with chaperone molecules or in the nucleus associated with DNA.
  • Nuclear hormone receptors are divided into several groups as follows: Thyroid hormone receptor; Retinoic acid receptor; Peroxisome proliferator-activated receptor; Rev-ErbA; RAR-related orphan receptor; Liver X receptor-like; Vitamin D receptor-like; NRs with two DNA binding domains; Hepatocyte nuclear factor-4; Retinoid X receptor; Testicular receptor; TLX/PNR; COUP/EAR; Estrogen receptor; Estrogen related receptor; 3-Ketosteroid receptors; NGFIB/NURR1/NOR1; SF1/LRH1; GCNF; and DAX/SHP.
  • Nuclear hormone receptors are denoted by an NRNC Symbol: NR1A1; NR1A2; NR1B1; NR1B2; NR1B3; NR1C1; NR1C2; NR1C3; NR1D1; NR1D2; NR1F1; NR1F2; NR1F3; NR1H3; NR1H2; NR1H4; NR1H5[44]; NR1I1; NR1I2; NR1I3; NR1X1; NR1X2; NR1X3; NR2A1; NR2A2; NR2B1; NR2B2; NR2B3; NR2C1; NR2C2; NR2E1; NR2E3; NR2F1; NR2F2; NR2F6; NR3A1; NR3A2; NR3B1; NR3B2
  • the bait or prey polypeptide comprises any one or more of: NR1A1; NR1A2; NR1B1; NR1B2; NR1B3; NR1C1; NR1C2; NR1C3; NR1D1; NR1D2; NR1F1; NR1F2; NR1F3; NR1H3; NR1H2; NR1H4; NR1H5[44]; NR1I1; NR1I2; NR1I3; NR1X1; NR1X2; NR1X3; NR2A1; NR2A2; NR2B1; NR2B2; NR2B3; NR2C1; NR2C2; NR2E1; NR2E3; NR2F1; NR2F2; NR2F6; NR3A1; NR3A2; NR3B1; NR3B
  • the methods used herein will be used to interrogate one or a small number of bait polypeptides compared to a large number of prey polypeptides.
  • multiple GPCRs might interact with a single G ⁇ subunit.
  • a common G ⁇ (the bait polypeptide) may be tested with a large amount of GPCRs (prey polypeptide).
  • the prey polypeptide is supplied as a plurality of prey polypeptides, encoded by a plurality of nucleic acids, that interact or potentially interact with a single bait polypeptide.
  • the system described above can be effectively utilized using a variety of methods.
  • the system is useful in methods to interrogate protein-protein interactions, both at a steady-state and in response to a physical or chemical stimulus.
  • the reporter element comprises a UMI mated to a particular prey polypeptide the system can be deployed in a multiplexed assay.
  • a plurality of cells are incubated in one well of a multi-well plate.
  • the plurality of cells are transfected with a plurality of nucleic acids encoding a library of prey polypeptides coupled to a transcription regulating polypeptide and comprising reporter elements with a prey polypeptide specific UMI.
  • the cells can already comprise a nucleic acid encoding a bait polypeptide, or the nucleic acid encoding the bait polypeptide can be transfected along with the prey polypeptide.
  • the transfected cells are then contacted with a chemical stimulus, after a sufficient amount of time to allow for expression of a reporter gene comprising the UMI, cell lysates are harvested, mRNA is reverse transcribed, and sequencing of the UMIs is performed by a next-generation sequencing technology. Sequencing results will indicate if transcription was activated, and the magnitude of any activation. In this example, activation would be indicative of a chemical stimulus causing the prey polypeptide to closely associate with the bait polypeptide. If the prey polypeptide comprises a transcriptional repressor then the opposite interaction can be interrogated (e.g., a chemical stimulus leading to disruption of a protein-protein interaction).
  • the assays are carried out in multiwell formats such as 6, 12, 24, 48, 96, or 384-well format.
  • each well is supplied with a different test chemical, or the test chemicals are supplied in duplicate, triplicate, or quadruplicate wells.
  • the assay can also comprise one or more positive or a negative control wells.
  • the systems, nucleic acids, and methods described herein rely on molecular complementation of two fragments of a cleavable molecule.
  • the bait polypeptide comprises a first fragment and the prey polypeptide comprises a second fragment. While the first and second fragment can overlap each fragment independently lacks full function. As a result, when the bait polypeptide and the prey polypeptide are brought into proximity the first and second fragment combine to form a single cleavable molecule.
  • the cleavable molecule for use with the systems, nucleic acids, and methods described herein is a ubiquitin molecule.
  • Ubiquitin is a 76 amino acid protein that is highly conserved amongst eukaryotes and plays a key role in protein homeostasis. When ubiquitin is added to a polypeptide it marks that polypeptide for destruction by various cellular processes. Ubiquitin is recycled by cleavage from the marked polypeptide by a deubiquitinating enzyme.
  • the Ubiquitin-60S ribosomal protein L40 comprises the following sequence: MQIFVKTLTGKTITLEVEPSDTIENVKAKIQDKEGIPPDQQRLIFA GKQLEDGRTLSDYNIQKESTLHLVLRLRGG (SEQ ID NO: 1).
  • the nucleic acids described herein encode a fragment of a ubiquitin molecule at least about 25, 30, 35, 40, 45, or 50 amino acids in length, or any integer therein, and at least about 90%, 95%, 97%, 98%, 99%, or 100% identical to that set forth in SEQ ID NO: 1.
  • a first fragment of a ubiquitin polypeptide is a C-terminal fragment of a ubiquitin polypeptide (Cub), and a second fragment of a ubiquitin polypeptide is an N-terminal fragment of a ubiquitin polypeptide (Nub).
  • a first fragment of a ubiquitin polypeptide is an N-terminal fragment of a ubiquitin polypeptide (Nub)
  • a second fragment of a ubiquitin polypeptide is a C-terminal fragment of a ubiquitin polypeptide (Cub).
  • the systems, nucleic acids, and methods described herein rely on molecular complementation of two fragments of a protease molecule.
  • the bait polypeptide comprises a first fragment and the prey polypeptide comprises a second fragment. While the first and second fragment can overlap each fragment independently lacks full function. As a result, when the bait polypeptide and the prey polypeptide are brought into proximity the first and second fragment combine to form a single functional protease molecule.
  • the functional protease for use with the methods, nucleic acids, and systems described herein is a from Tobacco Etch Virus nuclear - inclusion - a endopeptidase (TEV protease).
  • TEV is a member of the PA clan of chymotrypsin-like proteases.
  • TEV The amino acid sequence of TEV is set forth in SLFKGPRDYNPIS STICHLTNESDGHTTSLYGIGFGPFIITNKHLFRRNNGTLLVQSLHGVF KVKNTTTLQQHLIDGRDMIIIRMPKDFPPFPQKLKFREPQREERICLVTTNFQTKSMSSMV SDTSCTFPSSDGIFWKHWIQTKDGQCGSPLVSTRDGFIVGIHSASNFTNTNNYFTSVPKNF MELLTNQEAQQWVSGWRLNADSVLWGGHKVFMVKPEEPFQPVKEATQLMN SEQ ID NO: 2.
  • the nucleic acids described herein encode a fragment of a TEV at least about 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 amino acids in length, or any integer therein, and at least about 90%, 95%, 97%, 98%, 99%, or 100% identical to that set forth in SEQ ID NO: X.
  • TEV is highly specific and cleaves a polypeptide comprising the amino acid sequence EXLY ⁇ Q ⁇ where X is any residue, ⁇ is any large or medium hydrophobic residue and ⁇ is any small hydrophobic or polar residue. TEV exhibits optimal efficiency against the ENLYFQ ⁇ S amino acid sequence.
  • a first fragment of a TEV polypeptide is a C-terminal fragment of a TEV polypeptide (CTEV), and a second fragment of a TEV polypeptide is an N-terminal fragment of a TEV polypeptide (NTEV).
  • CTEV C-terminal fragment of a TEV polypeptide
  • NTEV N-terminal fragment of a TEV polypeptide
  • a first fragment of a TEV polypeptide is an N-terminal fragment of a TEV polypeptide (NTEV)
  • a second fragment of a TEV polypeptide is a C-terminal fragment of a ubiquitin polypeptide (CTEV).
  • a transcription regulating polypeptide is further present coupled to the bait polypeptide or the prey polypeptide.
  • the transcription regulating polypeptide Upon molecular complementation of a split cleavage molecule or a split cleavable molecule the transcription regulating polypeptide is cleaved and released in an active form. This cleavage can be affected by either an endogenous enzyme (e.g., a deubiquitinating enzyme), or by the action of the split molecule itself (e.g., a reconstituted TEV protease).
  • a transcription regulating polypeptide is coupled to the prey polypeptide.
  • a transcription regulating polypeptide is coupled to the bait polypeptide.
  • the system comprises two transcription regulating polypeptides that are coupled to the same polypeptide or different polypeptides.
  • the prey polypeptide is coupled to a transcription regulating polypeptide; and the bait polypeptide is coupled to a transcription regulating polypeptide.
  • the transcription regulating polypeptide is a transcription factor.
  • the system described herein is compatible with any transcription factor commonly or potentially useable in a reporter assay.
  • Common transcription factors used include LexA, Gal4, VP16 (from Herpes Simplex Virus), heat shock factor (HSF), NFAT, or CREB.
  • the transcription factor is a synthetic transcription factor comprising a DNA bonding domain from a first transcription factor, and a transcription regulating domain from a second transcription factor.
  • the transcription factor comprises a GAL4-VP16 chimeric transcription factor.
  • the transcription factor comprises a GAL4-VPR chimeric transcription factor.
  • the sequence of the Gal4-VPR chimeric transcription factor is given by the sequence set forth in MKLLSSIEQACDICRLKKLKCSKEKPKCAKCLKNNWECRYSPKTKRSPLTRAHLTEVE SRLERLEQLFLLIFPREDLDMILKMDSLQDIKALLTGLFVQDNVNKDAVTDRLASVETD MPLTLRQHRISATSSSEESSNKGQRQLTVSASGSGRAGKPIPNPLLGLDSTDALDDFDLD MLGSDALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLDMLGSPKKKRKVGSQYLPD TDDRHRIEEKRKRTYETFKSIMKKSPFSGPTDPRPPPRRIAVPSRSSASVPKPAPQPYPFTS SLSTINYDEFPTMVFPSGQISQASALAPAPPQVLPQAPAPAPAPAMVSALAQAPAPVPVL APGPPQAVAPPAPKPTQAGEGTLSEALLQLQFDDEDLGALLGNSTDPAVFTDLASVDNS
  • the system can provide information on a loss of protein-protein interaction, by employing a transcriptional repressor.
  • the transcription regulating polypeptide is a transcriptional repressor.
  • the transcriptional repressor comprises a KRAB domain (sequence RTLVTFKDVFVDFTR EEWKLLDTAQQIVYRNVMLENYKNLVSLGYQLTKPDVILRLEKGEEP) SEQ ID NO: 4.
  • the transcriptional repressor is a synthetic repressor comprising a DNA bonding domain from a first transcription factor, and a transcriptional repressor domain from a transcriptional repressor protein.
  • the transcriptional repressor with an amino acid sequence at least about 90%, 95%, 97%, 98%, 99%, or 100% identical to that set forth in SEQ ID NO: 4.
  • the transcription regulating polypeptide is a synthetic transcription factor
  • Synthetic transcription factors are artificial proteins capable of targeting and modulating gene expression. Some synthetic transcription factors are chimeric proteins containing domains from multiple different genes. In certain embodiments, synthetic transcription factors comprise a DNA binding domain from one gene and transcriptional regulatory domain from another gene.
  • said synthetic transcription factor has a higher specificity for a regulatory element nucleotide sequence than any endogenous transcription factor. In certain embodiments, said synthetic transcription factor binds a synthetic transcription factor promoter nucleotide sequence not capable of being bound by an endogenous promoter. In certain embodiments, said synthetic transcription factor results in less background production of a reporter than would occur with use of an endogenous transcription factor.
  • said DNA binding domain is non-endogenous to a cell containing a transcriptional relay system of the present invention.
  • said DNA binding domain from a first transcription factor is from Gal4, PPR1, LexA, Lac9, or combinations thereof.
  • said DNA binding domain comprises an amino acid sequence set forth in MKLLS SIEQACDICRLKKLKCSKEKPKCAKCLKNNWECRYSPKTKRSPLTRAHLTEVES RLERLEQLFLLIFPREDLDMILKMDSLQDIKALLTGLFVQDNVNKDAVTDRLASVETDM PLTLRQHRISATSSSEESSNKGQRQLTVS, SEQ ID NO: 21.
  • said DNA binding domain comprises an amino acid sequence set forth in MKKKNSKKSNRTDSKRGDSNGSKSRTACKRCRKKKCDSCKRCAKVCVSDATGKDVRS YVDRAVMIVIRVKYGVDTKRGNATSDDDKKYSSVSS, SEQ ID NO: 22.
  • said DNA binding domain comprises an amino acid sequence set forth in MKSRTACKRCRLKKIKCDQEFPSCKRCAKLEVPCYSPKTKRSPLTRAHLTEVESRLERLE QLFLLIFPREDLDMILKMDSLQDIKALLTGLFVQDNVNKDAVTDRLASVETDMPLTLRQ HRISATSSSEESSNKGQRQLTVS, SEQ ID NO: 23.
  • said DNA binding domain comprises an amino acid sequence set forth in MKSRTACKRCRLKKIKCDQEFPSCKRCAKLEVPCVSSPKTKRSPLTRAHLTEVESRLERL EQLFLLIFPREDLDMILKMDSLQDIKALLTGLFVQDNVNKDAVTDRLASVETDMPLTLR QHRISATSSSEESSNKGQRQLTVS, SEQ ID NO: 24.
  • said DNA binding domain comprises an amino acid sequence set forth in MNKKSSEVMHQACDACRKKKWKCSKTVPTCTNCLKYNLDCVYSPQVVRTPLTRAHLT EMENRVAELEQFLKELFPVWDIDRLLQQKDTYRIRELLTMGSTNTVPGLASNNIDSSLEQ PVAFGTAQPAQSLSTDPAVQSQAYPMQPV, SEQ ID NO: 25.
  • said DNA binding domain comprises an amino acid sequence set forth in MNKKSSEVMHQACVECRQQKSKCDAHERAPEPCTKCAKKNVPCIVYSPQVVRTPLTRA HLTEMENRVAELEQFLKELFPVWDIDRLLQQKDTYRIRELLTMGSTNTVPGLASNNIDSS LEQPVAFGTAQPAQSLSTDPAVQSQAYPMQPV, SEQ ID NO: 26.
  • said DNA binding domain comprises an amino acid sequence set forth in MNKKSSEVMHQACKRCRLKKIKCDQEFPSCKRCLKYNLDCVYSPQVVRTPLTRAHLTE MENRVAELEQFLKELFPVWDIDRLLQQKDTYRIRELLTMGSTNTVPGLASNNIDSSLEQP VAFGTAQPAQSLSTDPAVQSQAYPMQPV, SEQ ID NO: 27.
  • said DNA binding domain comprises an amino acid sequence set forth in MNKKSSEVMHQACKRCRLKKIKCDQEFPSCKRCAKLEVPCVYSPQVVRTPLTRAHLTE MENRVAELEQFLKELFPVWDIDRLLQQKDTYRIRELLTMGSTNTVPGLASNNIDSSLEQP VAFGTAQPAQSLSTDPAVQSQAYPMQPV, SEQ ID NO: 28.
  • said DNA binding domain comprises an amino acid sequence variant of SEQ ID NO: 1.
  • the amino acid sequence variant of SEQ ID NO: 1 is R15W, K23P, K23T, K23W, K23M, K23N, F68R, F68Q, L69P, L70P, Q9E, Q9A, Q9N, R15K, R15A, R15M, K18R, K18A, K18M, K23R, K23A, K23M, or combinations thereof.
  • the amino acid sequence variant of SEQ ID NO: 21 is R15W. In certain embodiments, the amino acid sequence variant of SEQ ID NO: 21 is K23P.
  • the amino acid sequence variant of SEQ ID NO: 21 is K23T. In certain embodiments, the amino acid sequence variant of SEQ ID NO: 21 is K23W. In certain embodiments, the amino acid sequence variant of SEQ ID NO: 21 is K23M. In certain embodiments, the amino acid sequence variant of SEQ ID NO: 21 is K23N. In certain embodiments, the amino acid sequence variant of SEQ ID NO: 21 is F68R. In certain embodiments, the amino acid sequence variant of SEQ ID NO: 21 is F68Q. In certain embodiments, the amino acid sequence variant of SEQ ID NO: 21 is L69P. In certain embodiments, the amino acid sequence variant of SEQ ID NO: 21 is L70P.
  • the amino acid sequence variant of SEQ ID NO: 21 is Q9E. In certain embodiments, the amino acid sequence variant of SEQ ID NO: 21 is Q9A. In certain embodiments, the amino acid sequence variant of SEQ ID NO: 21 is Q9N. In certain embodiments, the amino acid sequence variant of SEQ ID NO: 21 is R15K. In certain embodiments, the amino acid sequence variant of SEQ ID NO: 21 is R15A. In certain embodiments, the amino acid sequence variant of SEQ ID NO: 21 is R15M. In certain embodiments, the amino acid sequence variant of SEQ ID NO: 21 is K18R. In certain embodiments, the amino acid sequence variant of SEQ ID NO: 21 is K18A.
  • the amino acid sequence variant of SEQ ID NO: 21 is K18M. In certain embodiments, the amino acid sequence variant of SEQ ID NO: 21 is K23R. In certain embodiments, the amino acid sequence variant of SEQ ID NO: 21 is K23A. In certain embodiments, the amino acid sequence variant of SEQ ID NO: 21 is K23M.
  • said transcription activating domain from a second transcription factor is from VP64, p65, and Rta, and combinations thereof.
  • said transcription activating domain comprises the amino acid sequence set forth in: RAGKPIPNPLLGLDSTDALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLDMLGSD ALDDFDLDMLGSPKKKRKVGSQYLPDTDDRHRIEEKRKRTYETFKSIMKKSPF SGPTDP RPPPRRIAVPSRSSASVPKPAPQPYPFTSSLSTINYDEFPTMVFPSGQISQASALAPAPPQVL PQAPAPAPAMVSALAQAPAPVPVLAPGPPQAVAPPAPKPTQAGEGTLSEALLQLQFD DEDLGALLGNSTDPAVFTDLASVDNSEFQQLLNQGIPVAPHTTEPMLMEYPEAITRLVTG AQRPPDPAPAPLGAPGLPNGLLSGDEDFSSIADMDFSALLSQISSGSGSGSRDSREGMFLP K
  • the nucleic acids described herein encode a transcription factor with a VPR amino acid sequence at least 90% 95%, 97%, 98%, 99%, or 100% identical to that set forth in SEQ ID NO: 14. In certain embodiments, the nucleic acids described herein encode a transcription factor with a VPR amino acid sequence at least 90% identical to that set forth in SEQ ID NO: 14. In certain embodiments, the nucleic acids described herein encode a transcription factor with a VPR amino acid sequence at least 95% identical to that set forth in SEQ ID NO: 14. In certain embodiments, the nucleic acids described herein encode a transcription factor with a VPR amino acid sequence at least 97% identical to that set forth in SEQ ID NO: 14.
  • the nucleic acids described herein encode a transcription factor with a VPR amino acid sequence at least 98% identical to that set forth in SEQ ID NO: 14. In certain embodiments, the nucleic acids described herein encode a transcription factor with a VPR amino acid sequence at least 99% identical to that set forth in SEQ ID NO: 14. In certain embodiments, the nucleic acids described herein encode a transcription factor with a VPR amino acid sequence 100% identical to that set forth in SEQ ID NO: 14.
  • a transcription activating domain on a synthetic transcription factor comprises an amino acid sequence variant that increases or decreases transcriptional activation.
  • said transcription activating domain comprising an amino acid sequence variant that increases or decreases transcriptional activation is a sequence variant of SEQ ID NO: 14.
  • a synthetic transcription factor encoded by a nucleic acid sequence of a transcription factor nucleic acid comprises a polypeptide sequence that destabilizes said synthetic transcription factors, also termed a “degron.”
  • said polypeptide sequence that destabilizes said transcription factor comprises a PEST polypeptide sequence.
  • a PEST polypeptide sequence is a polypeptide sequence containing a plurality of amino acids, wherein said polypeptide sequence is rich in the amino acids proline, glutamic acid, serine, and/or threonine.
  • said polypeptide sequence that destabilizes said transcription factor comprises a CL1 polypeptide sequence.
  • a CL1 polypeptide sequence may act as a degradation signal, leading to a shorter half-life of the resulting synthetic transcription factor.
  • said polypeptide sequence that destabilizes said synthetic transcription factor aids in reduction of background signal of a reporter.
  • said synthetic transcription factor comprises a GAL4-VP16 chimeric transcription factor.
  • the transcription factor comprises a GAL4-VPR chimeric transcription factor.
  • the sequence of the Gal4-VPR chimeric transcription factor is given by the sequence set forth in MKLLSSIEQACDICRLKKLKCSKEKPKCAKCLKNNWECRYSPKTKRSPLTRAHLTEVE SRLERLEQLFLLIFPREDLDMILKMDSLQDIKALLTGLFVQDNVNKDAVTDRLASVETD MPLTLRQHRISATSSSEESSNKGQRQLTVSASGSGRAGKPIPNPLLGLDSTDALDDFDLD MLGSDALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLDMLGSPKKKRKVGSQYLPD TDDRHRIEEKRKRTYETFKSIMKKSPFSGPTDPRPPPRRIAVPSRSSASVPKPAPQPYPFTS SLSTINYDEFPTMVFPSGQISQASALAPAPPQVLPQAP
  • the nucleic acids described herein encode a transcription factor with an amino acid sequence at least 90%, 95%, 97%, 98%, 99%, or 100% identical to that set forth in SEQ ID NO: 10. In certain embodiments, the nucleic acids described herein encode a transcription factor with an amino acid sequence at least 90% identical to that set forth in SEQ ID NO: 10. In certain embodiments, the nucleic acids described herein encode a transcription factor with an amino acid sequence at least 95% identical to that set forth in SEQ ID NO: 10. In certain embodiments, the nucleic acids described herein encode a transcription factor with an amino acid sequence at least 97% identical to that set forth in SEQ ID NO: 10.
  • the nucleic acids described herein encode a transcription factor with an amino acid sequence at least 98% identical to that set forth in SEQ ID NO: 10. In certain embodiments, the nucleic acids described herein encode a transcription factor with an amino acid sequence at least 99% identical to that set forth in SEQ ID NO: 10. In certain embodiments, the nucleic acids described herein encode a transcription factor with an amino acid sequence 100% identical to that set forth in SEQ ID NO: 10.
  • said synthetic transcription factor comprises a Gal4 DNA binding domain given by the amino acid sequence set forth in SEQ ID NO: 21. In certain embodiments, said synthetic transcription factor comprises a DNA binding domain with an amino acid sequence at least 90% 95%, 97%, 98%, 99%, or 100% identical to that set forth in SEQ ID NO: 21. In certain embodiments, said synthetic transcription factor comprises a DNA binding domain with an amino acid sequence at least 90% identical to that set forth in SEQ ID NO: 21. In certain embodiments, said synthetic transcription factor comprises a DNA binding domain with an amino acid sequence at least 95% identical to that set forth in SEQ ID NO: 21.
  • said synthetic transcription factor comprises a DNA binding domain with an amino acid sequence at least 97% identical to that set forth in SEQ ID NO: 21. In certain embodiments, said synthetic transcription factor comprises a DNA binding domain with an amino acid sequence at least 98% identical to that set forth in SEQ ID NO: 21. In certain embodiments, said synthetic transcription factor comprises a DNA binding domain with an amino acid sequence at least 99% identical to that set forth in SEQ ID NO: 21. In certain embodiments, said synthetic transcription factor comprises a DNA binding domain with an amino acid sequence 100% identical to that set forth in SEQ ID NO: 21.
  • said synthetic transcription factor comprises a transcription activating domain from VP64 given by the amino acid sequence set forth in RAGKPIPNPLLGLDSTDALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLDMLGSDAL DDFDLDMLGSPKKKRKV, SEQ ID NO: 11.
  • said synthetic transcription factor comprises a transcription activating domain with an amino acid sequence at least 90% 95%, 97%, 98%, 99%, or 100% identical to that set forth in SEQ ID NO: 11.
  • said synthetic transcription factor comprises a transcription activating domain with an amino acid sequence at least 90% identical to that set forth in SEQ ID NO: 11.
  • said synthetic transcription factor comprises a transcription activating domain with an amino acid sequence at least 95% identical to that set forth in SEQ ID NO: 11. In certain embodiments, said synthetic transcription factor comprises a transcription activating domain with an amino acid sequence at least 97% identical to that set forth in SEQ ID NO: 11. In certain embodiments, said synthetic transcription factor comprises a transcription activating domain with an amino acid sequence at least 98% identical to that set forth in SEQ ID NO: 11. In certain embodiments, said synthetic transcription factor comprises a transcription activating domain with an amino acid sequence at least 99% identical to that set forth in SEQ ID NO: 11. In certain embodiments, said synthetic transcription factor comprises a transcription activating domain with an amino acid sequence 100% identical to that set forth in SEQ ID NO: 11.
  • said synthetic transcription factor comprises a transcription activating domain from p65 given by the amino acid sequence set forth in QYLPDTDDRHRIEEKRKRTYETFKSIMKKSPFSGPTDPRPPPRRIAVPSRSSASVPKPAPQP YPFTSSLSTINYDEFPTMVFPSGQISQASALAPAPPQVLPQAPAPAPAMVSALAQAPAP VPVLAPGPPQAVAPPAPKPTQAGEGTLSEALLQLQFDDEDLGALLGNSTDPAVFTDLAS VDNSEFQQLLNQGIPVAPHTTEPMLMEYPEAITRLVTGAQRPPDPAPAPLGAPGLPNGLL SGDEDFSSIADMDFSALLSQISS, SEQ ID NO: 12.
  • said synthetic transcription factor comprises a transcription activating domain with an amino acid sequence at least 90% 95%, 97%, 98%, 99%, or 100% identical to that set forth in SEQ ID NO: 12. In certain embodiments, said synthetic transcription factor comprises a transcription activating domain with an amino acid sequence at least 90% identical to that set forth in SEQ ID NO: 12. In certain embodiments, said synthetic transcription factor comprises a transcription activating domain with an amino acid sequence at least 95% identical to that set forth in SEQ ID NO: 12. In certain embodiments, said synthetic transcription factor comprises a transcription activating domain with an amino acid sequence at least 97% identical to that set forth in SEQ ID NO: 12.
  • said synthetic transcription factor comprises a transcription activating domain with an amino acid sequence at least 98% identical to that set forth in SEQ ID NO: 12. In certain embodiments, said synthetic transcription factor comprises a transcription activating domain with an amino acid sequence at least 99% identical to that set forth in SEQ ID NO: 12. In certain embodiments, said synthetic transcription factor comprises a transcription activating domain with an amino acid sequence 100% identical to that set forth in SEQ ID NO: 12.
  • said synthetic transcription factor comprises a transcription activating domain from Rta given by the amino acid sequence set forth in RDSREGMFLPKPEAGSAISDVFEGREVCQPKRIRPFHPPGSPWANRPLPASLAPTPTGPVH EPVGSLTPAPVPQPLDPAPAVTPEASHLLEDPDEETSQAVKALREMADTVIPQKEEAAIC GQMDLSHPPPRGHLDELTTTLESMTEDLNLDSPLTPELNEILDTFLNDECLLHAMHISTG LSIFDTSLF, SEQ ID NO: 13.
  • said synthetic transcription factor comprises a transcription activating domain with an amino acid sequence at least 90% 95%, 97%, 98%, 99%, or 100% identical to that set forth in SEQ ID NO: 13.
  • said synthetic transcription factor comprises a transcription activating domain with an amino acid sequence at least 90% identical to that set forth in SEQ ID NO: 13. In certain embodiments, said synthetic transcription factor comprises a transcription activating domain with an amino acid sequence at least 95% identical to that set forth in SEQ ID NO: 13. In certain embodiments, said synthetic transcription factor comprises a transcription activating domain with an amino acid sequence at least 97% identical to that set forth in SEQ ID NO: 13. In certain embodiments, said synthetic transcription factor comprises a transcription activating domain with an amino acid sequence at least 98% identical to that set forth in SEQ ID NO: 13. In certain embodiments, said synthetic transcription factor comprises a transcription activating domain with an amino acid sequence at least 99% identical to that set forth in SEQ ID NO: 13. In certain embodiments, said synthetic transcription factor comprises a transcription activating domain with an amino acid sequence 100% identical to that set forth in SEQ ID NO: 13.
  • the reporter element minimally comprises a regulatory element that is able to be bound by the transcription regulating polypeptide and a reporter gene.
  • the reporter gene minimally comprises a unique molecular identifier (UMI).
  • UMI unique molecular identifier
  • a unique molecular identifier is a nucleotide sequence that is unique to a given prey polypeptide. Activation of the UMI reporter gene by the cleaved transcriptional activator can be determined by sequencing.
  • the reporter element comprises a UMI and an additional reporter gene selected from a fluorescent protein, a luciferase gene, a beta-galactosidase gene, a beta-glucuronidase gene, a chloramphenicol acetyltransferase gene, a secreted placental alkaline phosphatase gene.
  • these genes encode reporter polypeptides which can be assayed for a specific enzymatic activity, or in the case of a fluorescent reporter can be assayed for fluorescent emissions.
  • the fluorescent protein comprises a green fluorescent protein (GFP), a red fluorescent protein (RFP), a yellow fluorescent protein (YFP), or a cyan fluorescent protein (CFP).
  • the system described herein can utilize many different regulatory sequences that control activation of the reporter gene through transcription factor binding.
  • the regulatory sequence is one that can be bound by the transcription regulating polypeptide or the transcriptional repressor polypeptide detailed above. Generally, it will be configured so that the regulatory sequence is 5′ to the UMI, the reporter gene, or both.
  • the regulatory sequence comprises a Gal4-UAS, which is able to be bound by a Gal4-VPR chimeric transcription factor.
  • a UMI allows for multiplexing of different prey peptides in the same assay since transcription of the UMI will indicate association of a specific prey polypeptide with the bait.
  • the UMI can be any length that allows for sufficient diversity to allow multiplexed determination of an interaction between a bait polypeptide and at least 100, 500, 1,000, 2,000, 3,000, 4,000, 5,000, 6,000, 7,000, 8,000, 9,000, 10,000 prey polypeptides.
  • the UMI will be between 8 and 20 nucleotides in length, however it may be longer. In certain embodiments, the UMI is 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 nucleotides in length.
  • Reporter activation can be measured in any suitable way that allows sequence determination of the UMI, with a preference for methods that allow sequence determination in a multiplex fashion.
  • a next-generation sequencing technology is used to determine the sequence of the UMI.
  • Next generation sequencing encompasses many kinds of sequencing such as pyrosequencing, sequencing-by-synthesis, single-molecule sequencing, second-generation sequencing, nanopore sequencing, sequencing by ligation, or sequencing by hybridization.
  • Next-generation sequencing platforms are those commercially available from lllumina (RNA-Seq) and Helicos (Digital Gene Expression or “DGE”).
  • Next generation sequencing methods include, but are not limited to those commercialized by: 1) 454/Roche Lifesciences including but not limited to the methods and apparatus described in Margulies et al., Nature (2005) 437:376-380 (2005); and U.S. Pat. Nos. 7,244,559; 7,335,762; 7,211,390; 7,244,567; 7,264,929; 7,323,305; 2) Helicos Biosciences Corporation (Cambridge, Mass.) as described in U.S. application Ser. No. 11/167,046, and U.S. Pat. Nos. 7,501,245; 7,491,498; 7,276,720; and in U.S. Patent Application Publication Nos.
  • Activation of an additional reporter molecule can be determined using standard assays to detect a luciferase protein, a beta-galactosidase protein, a beta-glucuronidase protein, a chloramphenicol acetyltransferase protein, a secreted placental alkaline phosphatase protein, or a fluorescent protein.
  • these are enzymatic assays where a detectable signal is produced based upon the proteins enzymatic activity towards a substrate.
  • luciferase expression can be measured in the presence of a luciferase substrate by a luminometer.
  • a fluorescent reporter does not require a substrate, and the signal can be measured by fluorescence microscopy or a fluorescent plate reader. Fluorescent reporters are particularly useful for measuring reporter activation in live cells.
  • the nucleic acids described herein additionally comprise one or more additional genes that encode a selecting polypeptide or a marking polypeptide. In certain embodiments, the nucleic acids described herein additionally comprise one or more additional genes that encode a polypeptide that confers antibiotic resistance to a transfected cell.
  • the nucleic acids can comprise a selectable marker such as an antibiotic resistance gene that confers antibiotic resistance to neomycin/G418 resistance, puromycin resistance, zeocin resistance, or blasticidin resistance.
  • the nucleic acids described herein additionally comprise one or more additional genes that encode a polypeptide that comprises an epitope tag that is expressed on the cell surface.
  • the epitope tag comprises a c-Myc tag, a Hemagglutinin (HA) tag, a histidine tag, a V5 tag, or a FLAG tag.
  • the nucleic acids described herein additionally comprise one or more additional promotorless genes that encode a fluorescent polypeptide. Such genes are useful when transfection is intended to lead to integration and is targeted for a specific location or landing pad.
  • the “landing pad” in the cells genome comprises a promoter that can complement the lack of promotor in the pomotorless gene, and lead to expression of the promotorless gene only when the promoterless gene is integrated into the intended genomic location.
  • Cells with correct integration can be selected by flow cytometry and cell sorting. This type of marker can also ensure that only a single copy of an intended nucleic acid is integrated in the genome and help avoid ectopic overexpression.
  • a nucleic acid encoding a bait polypeptide comprises: a gene that encodes a polypeptide that confers antibiotic resistance to a transfected cell; a gene that encodes a polypeptide that comprises an epitope tag that is expressed on the cell surface; or a promotorless gene that encodes a fluorescent polypeptide.
  • Cells useful in the method described herein are generally those that are able to be easily rendered transgenic with one or more exogenous nucleic acids encoding the bait polypeptide, the prey polypeptide, or that comprise a reporter element.
  • the system nucleic acid(s) encoding a bait polypeptide, a prey polypeptide, and comprising a reporter element can be transfected or transduced into suitable cell line using methods known in the art, such as calcium phosphate transfection, lipid based transfection (e.g., LipofectamineTM, Lipofectamine-2000TM, Lipofectamine-3000TM, or Fugene® HD), electroporation, or viral transduction.
  • the cell can also be a population of cells of the same type grown to confluency or near confluency in an appropriate tissue culture vessel.
  • the cell used comprises a stable integration of either the nucleic acid encoding a bait polypeptide, the nucleic acid comprising the reporter element, or both.
  • Stable cell lines can be made using random integration of a linearized nucleic acid, virally or transposon directed integration, or directed integration, for example using site specific recombination between an AttP and an AttB site.
  • the cell comprises a single genomic integration of the nucleic acid encoding the bait polypeptide.
  • the cell comprises a single genomic integration of the nucleic acid comprising the reporter element.
  • the cell comprises a single integration of the nucleic acid encoding the bait polypeptide, and a single genomic integration of the nucleic acid comprising the reporter element.
  • the cell or cell population used in the system is a eukaryotic cell.
  • the cell or cell population is a mammalian cell.
  • the cell or cell population is a human cell.
  • the cell or cell population is SH-SY5Y, Human neuroblastoma; Hep G2, Human Caucasian hepatocyte carcinoma; 293 (also known as HEK 293), Human Embryo Kidney; RAW 264.7, Mouse monocyte macrophage; HeLa, Human cervix epitheloid carcinoma; MRC-5 (PD 19), Human fetal lung; A2780, Human ovarian carcinoma; CACO-2, Human Caucasian colon adenocarcinoma; THP 1, Human monocytic leukemia; A549, Human Caucasian lung carcinoma; MRC-5 (PD 30), Human fetal lung; MCF7, Human Caucasian breast adenocarcinoma; SNL 76/7, Mouse SIM strain embryonic fibroblast; C2
  • a screen using a split-ubiquitin or split-TEV system is used to screen for potential compounds that induce GPCR signaling.
  • plate cells in a 96-well assay plate at 30,000 cells/well. Plate the cells in 100 uL DMEM+10% FBS and add 50 uL OPTIMEM with 50-300 ng/mL doxycycline, depending on level of GPCR induction desired, 15 ug/mL cumate (for split-ubiquitin) or 7.5 ug/mL cumate (for dual-split-TEV).
  • the cells in this example comprise a stably integrated nucleic acid encoding the bait protein, and a plurality of nucleic acids encoding a prey protein transiently transfected.
  • a test compound at desired concentration in 50 uL OPTIMEM to each well.
  • lysis buffer for either luciferase activity assay or for RNA extraction.
  • RNA can be extracted using standard methods or kits.
  • RNA can be quantified by standard downstream assays such as RT-qPCR or RNASeq.
  • Luciferase activity can be assayed using the Promega Bright-Glo system and can be read on a standard luminometer such as a Thermo Fisher Luminoskan, while RNAseq can be performed on an Illumina MiSeq after sequencing library preparation.
  • An exemplary induction of luciferase is shown in FIG. 2 .
  • a spit-TEV or split-UB system is deployed to determine the agonistic response to a given chemical stimulus, in this case the ⁇ 1 adrenergic agonist Xamoterol.
  • a library of cell lines was constructed in either the split-ubiquitin ( FIG. 3A ) or split-TEV ( FIG. 3B ) configuration.
  • This library comprises a library of cells each expressing different GPCR prey proteins each paired to a unique RNA barcode.
  • cells were plated in a poly-L-lysine coated 384-well assay plate at 22,000 cells/well in 25 uL DMEM+10% FBS.
  • the media was replaced with 25 uL OPTI-MEM with 1000 ng/mL doxycycline and 120 ug/mL cumate.
  • RNA extraction was added for RNA extraction.
  • the extracted RNAs were reverse transcribed and amplified in a single step with Luna One-Step RT-qPCR mix to prepare sequencing libraries, and levels of RNA barcode are quantified by RNAseq.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Mechanical Engineering (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Sustainable Development (AREA)
  • Human Computer Interaction (AREA)
  • Multimedia (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
US17/299,728 2018-12-07 2019-12-06 Systems for protein-protein interaction screening Pending US20220162667A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US17/299,728 US20220162667A1 (en) 2018-12-07 2019-12-06 Systems for protein-protein interaction screening

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862776992P 2018-12-07 2018-12-07
PCT/US2019/064969 WO2020118198A1 (en) 2018-12-07 2019-12-06 Systems for protein-protein interaction screening
US17/299,728 US20220162667A1 (en) 2018-12-07 2019-12-06 Systems for protein-protein interaction screening

Publications (1)

Publication Number Publication Date
US20220162667A1 true US20220162667A1 (en) 2022-05-26

Family

ID=69106181

Family Applications (2)

Application Number Title Priority Date Filing Date
US16/705,504 Active 2040-10-04 US11354926B2 (en) 2018-12-07 2019-12-06 Ultrasound fingerprint detection and related apparatus and methods
US17/299,728 Pending US20220162667A1 (en) 2018-12-07 2019-12-06 Systems for protein-protein interaction screening

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US16/705,504 Active 2040-10-04 US11354926B2 (en) 2018-12-07 2019-12-06 Ultrasound fingerprint detection and related apparatus and methods

Country Status (9)

Country Link
US (2) US11354926B2 (ja)
EP (1) EP3891279A1 (ja)
JP (1) JP2022509850A (ja)
KR (1) KR20210125476A (ja)
CN (1) CN113454217A (ja)
AU (1) AU2019392906A1 (ja)
CA (1) CA3121805A1 (ja)
MA (1) MA54392A (ja)
WO (1) WO2020118198A1 (ja)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7026111B2 (ja) * 2016-06-20 2022-02-25 バタフライ ネットワーク，インコーポレイテッド 微細加工超音波トランスデューサのための電気接点配置
US11501562B2 (en) 2019-04-30 2022-11-15 Bfly Operations, Inc. Ultrasound face scanning and identification apparatuses and methods
US11087109B1 (en) * 2020-07-27 2021-08-10 Qualcomm Incorporated Apparatus and method for ultrasonic fingerprint and force sensing
WO2022187467A2 (en) * 2021-03-04 2022-09-09 Butterfly Network, Inc. Micromachined ultrasound transducer with pedestal

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750341A (en) 1995-04-17 1998-05-12 Lynx Therapeutics, Inc. DNA sequencing by parallel oligonucleotide extensions
US7875440B2 (en) 1998-05-01 2011-01-25 Arizona Board Of Regents Method of determining the nucleotide sequence of oligonucleotides and DNA molecules
US7501245B2 (en) 1999-06-28 2009-03-10 Helicos Biosciences Corp. Methods and apparatuses for analyzing polynucleotide sequences
US7244559B2 (en) 1999-09-16 2007-07-17 454 Life Sciences Corporation Method of sequencing a nucleic acid
US7211390B2 (en) 1999-09-16 2007-05-01 454 Life Sciences Corporation Method of sequencing a nucleic acid
US6936702B2 (en) 2000-06-07 2005-08-30 Li-Cor, Inc. Charge-switch nucleotides
ATE497603T1 (de) * 2001-03-02 2011-02-15 Gpc Biotech Ag Drei-hybrid-assaysystem
DE10211063A1 (de) * 2002-03-13 2003-10-09 Axaron Bioscience Ag Neue Verfahren zur Detektion und Analyse von Protein-Interaktionen in vivo
EP1348766B1 (en) * 2002-03-28 2006-12-13 Dualsystems Biotech AG Method and kit for detecting membrane protein-protein interactions
DE602004024034D1 (de) 2003-01-29 2009-12-24 454 Corp Nukleinsäureamplifikation auf basis von kügelchenemulsion
US7745116B2 (en) 2003-04-08 2010-06-29 Pacific Biosciences Of California, Inc. Composition and method for nucleic acid sequencing
US20070224615A1 (en) * 2003-07-09 2007-09-27 Invitrogen Corporation Methods for assaying protein-protein interactions
WO2005014804A2 (en) * 2003-08-06 2005-02-17 Novartis Ag Ubiquitin-specific protease
US20060188890A1 (en) * 2003-10-31 2006-08-24 Proteologics, Inc. Ubiquitin-based protein interaction assays and related compositions
US7169560B2 (en) 2003-11-12 2007-01-30 Helicos Biosciences Corporation Short cycle methods for sequencing polynucleotides
KR100561851B1 (ko) 2003-11-18 2006-03-16 삼성전자주식회사 지문 인식 센서 및 그 제조 방법
US7462452B2 (en) 2004-04-30 2008-12-09 Pacific Biosciences Of California, Inc. Field-switch sequencing
US20060024711A1 (en) 2004-07-02 2006-02-02 Helicos Biosciences Corporation Methods for nucleic acid amplification and sequence determination
US7276720B2 (en) 2004-07-19 2007-10-02 Helicos Biosciences Corporation Apparatus and methods for analyzing samples
US20060024678A1 (en) 2004-07-28 2006-02-02 Helicos Biosciences Corporation Use of single-stranded nucleic acid binding proteins in sequencing
US7170050B2 (en) 2004-09-17 2007-01-30 Pacific Biosciences Of California, Inc. Apparatus and methods for optical analysis of molecules
JP2008513782A (ja) 2004-09-17 2008-05-01 パシフィック バイオサイエンシーズ オブ カリフォルニア， インコーポレイテッド 分子解析のための装置及び方法
WO2006042144A2 (en) 2004-10-07 2006-04-20 Ultra-Scan Corporation Ultrasonic fingerprint scanning utilizing a plane wave
EP1817572A2 (en) 2004-11-16 2007-08-15 Helicos Biosciences Corporation An optical train and method for tirf single molecule detection and analysis
US7462468B1 (en) 2005-01-28 2008-12-09 Pacific Biosciences Of California, Inc. DNA intercalating agents and methods of use
AU2006211150A1 (en) 2005-01-31 2006-08-10 Pacific Biosciences Of California, Inc. Use of reversible extension terminator in nucleic acid sequencing
US20060286566A1 (en) 2005-02-03 2006-12-21 Helicos Biosciences Corporation Detecting apparent mutations in nucleic acid sequences
US7405281B2 (en) 2005-09-29 2008-07-29 Pacific Biosciences Of California, Inc. Fluorescent nucleotide analogs and uses therefor
US20080269476A1 (en) 2006-04-26 2008-10-30 Helicos Biosciences Corporation Molecules and methods for nucleic acid sequencing
CA2653202A1 (en) 2006-05-25 2008-06-05 Ultra-Scan Corporation Biometrical object reader having an ultrasonic wave manipulation device
EP2405272B1 (en) * 2006-06-30 2015-01-14 DiscoveRx Corporation Detectable nucleic acid tag
US8354997B2 (en) 2006-10-31 2013-01-15 Navisense Touchless user interface for a mobile device
US7767805B2 (en) 2007-05-03 2010-08-03 Helicos Biosciences Corporation Methods and compositions for sequencing a nucleic acid
CA2689626C (en) 2007-06-06 2016-10-25 Pacific Biosciences Of California, Inc. Methods and processes for calling bases in sequence by incorporation methods
CN101802220B (zh) 2007-07-26 2013-07-31 加利福尼亚太平洋生物科学股份有限公司 分子冗余测序法
AU2009243918A1 (en) 2008-05-07 2009-11-12 Signostics Limited Docking system for medical diagnostic scanning using a handheld device
US20110265192A1 (en) * 2008-09-05 2011-10-27 Syddansk Universitet Nuclear receptor sensor system in transgenic animal
US9533873B2 (en) 2013-02-05 2017-01-03 Butterfly Network, Inc. CMOS ultrasonic transducers and related apparatus and methods
CN105307975B (zh) 2013-03-15 2017-04-26 蝴蝶网络有限公司 互补金属氧化物半导体(cmos)超声换能器及其形成方法
CA2903479C (en) 2013-03-15 2023-10-10 Butterfly Network, Inc. Monolithic ultrasonic imaging devices, systems and methods
JP6315893B2 (ja) * 2013-04-18 2018-04-25 キヤノン株式会社 被検体情報取得装置、被検体情報取得方法、及びプログラム
KR102305274B1 (ko) 2013-07-16 2021-09-24 더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 Mut 지문 id 시스템
US9592030B2 (en) * 2013-07-23 2017-03-14 Butterfly Network, Inc. Interconnectable ultrasound transducer probes and related methods and apparatus
US9984270B2 (en) 2013-08-05 2018-05-29 Apple Inc. Fingerprint sensor in an electronic device
CA2929723C (en) 2013-12-12 2020-09-15 Qualcomm Incorporated Micromechanical ultrasonic transducers and display
US9067779B1 (en) 2014-07-14 2015-06-30 Butterfly Network, Inc. Microfabricated ultrasonic transducers and related apparatus and methods
US9524415B2 (en) 2014-07-18 2016-12-20 Qualcomm Incorporated Test techniques for assessing ultrasonic fingerprint sensors
US10008659B2 (en) 2014-12-09 2018-06-26 Lg Innotek Co., Ltd. Fingerprint sensor
WO2016091624A1 (en) 2014-12-11 2016-06-16 Koninklijke Philips N.V. Two-terminal cmut device
US20160009544A1 (en) 2015-03-02 2016-01-14 Butterfly Network, Inc. Microfabricated ultrasonic transducers and related apparatus and methods
EP3265801B1 (en) * 2015-03-05 2020-06-17 Koninklijke Philips N.V. Ultrasound system and method
US10497748B2 (en) 2015-10-14 2019-12-03 Qualcomm Incorporated Integrated piezoelectric micromechanical ultrasonic transducer pixel and array
US9710689B2 (en) 2015-10-30 2017-07-18 Essential Products, Inc. Fingerprint sensors for mobile devices
US11813639B2 (en) * 2016-05-03 2023-11-14 Vanguard International Semiconductor Singapore Pte. Ltd. Electrode arrangement for a pMUT and pMUT transducer array
US10445547B2 (en) 2016-05-04 2019-10-15 Invensense, Inc. Device mountable packaging of ultrasonic transducers
US10452887B2 (en) 2016-05-10 2019-10-22 Invensense, Inc. Operating a fingerprint sensor comprised of ultrasonic transducers
US10408797B2 (en) 2016-05-10 2019-09-10 Invensense, Inc. Sensing device with a temperature sensor
JP7026111B2 (ja) 2016-06-20 2022-02-25 バタフライ ネットワーク，インコーポレイテッド 微細加工超音波トランスデューサのための電気接点配置
US10856840B2 (en) 2016-06-20 2020-12-08 Butterfly Network, Inc. Universal ultrasound device and related apparatus and methods
US10235552B2 (en) 2016-10-12 2019-03-19 Qualcomm Incorporated Hybrid capacitive and ultrasonic sensing
US10410034B2 (en) * 2016-11-07 2019-09-10 Qualcomm Incorporated Ultrasonic biometric system with harmonic detection
US20180203017A1 (en) * 2016-12-30 2018-07-19 The Board Of Trustees Of The Leland Stanford Junior University Protein-protein interaction detection systems and methods of use thereof
US10196261B2 (en) 2017-03-08 2019-02-05 Butterfly Network, Inc. Microfabricated ultrasonic transducers and related apparatus and methods
KR102433315B1 (ko) * 2017-12-27 2022-08-16 삼성전자주식회사 초음파 트랜스듀서가 임베디드된 유기 발광 다이오드 패널 및 이를 포함하는 표시 장치
EP3745961A4 (en) 2018-01-30 2021-11-10 Butterfly Network, Inc. METHODS AND DEVICES FOR PACKAGING ULTRASONIC-ON-A-CHIP
EP3762155B1 (en) 2018-03-09 2023-12-13 BFLY Operations, Inc. Methods for fabricating ultrasound transducer devices
WO2019213448A1 (en) 2018-05-03 2019-11-07 Butterfly Network, Inc. Vertical packaging for ultrasound-on-a-chip and related methods
WO2019213449A2 (en) 2018-05-03 2019-11-07 Butterfly Network, Inc. Ultrasound devices
US11018068B2 (en) 2018-07-06 2021-05-25 Butterfly Network, Inc. Methods and apparatuses for packaging an ultrasound-on-a-chip
US20200184176A1 (en) 2018-12-07 2020-06-11 Butterfly Network, Inc. Ultrasound fingerprint detection and related apparatus and methods

Also Published As

Publication number Publication date
JP2022509850A (ja) 2022-01-24
WO2020118198A1 (en) 2020-06-11
CA3121805A1 (en) 2020-06-11
CN113454217A (zh) 2021-09-28
MA54392A (fr) 2021-10-13
KR20210125476A (ko) 2021-10-18
EP3891279A1 (en) 2021-10-13
US20200184177A1 (en) 2020-06-11
AU2019392906A1 (en) 2021-07-22
US11354926B2 (en) 2022-06-07

Similar Documents

Publication Publication Date Title
US20220162667A1 (en) Systems for protein-protein interaction screening
Gromadzka et al. A short conserved motif in ALYREF directs cap-and EJC-dependent assembly of export complexes on spliced mRNAs
Randall et al. Different Smad2 partners bind a common hydrophobic pocket in Smad2 via a defined proline‐rich motif
Fouquet et al. Focal adhesion kinase is involved in rabies virus infection through its interaction with viral phosphoprotein P
JP5303448B2 (ja) 親和性が減少した酵素の相補性レポーター系を用いた分子相互作用の検出
US6114111A (en) Mammalian protein interaction cloning system
US6251676B1 (en) Mammalian cell two-hybrid system
EP2985347B1 (en) Method for detecting protein stability and uses thereof
US8148110B2 (en) Detection of molecular interactions by β-lactamase reporter fragment complementation
Chen et al. DAXX interacts with phage ΦC31 integrase and inhibits recombination
JP6323868B2 (ja) 核小体ストレス応答を誘導する薬剤の探索のためのポリペプチドの組み合わせ及びスクリーニング方法
JP2009529893A (ja) タンパク質−タンパク質相互作用のアッセイ方法
US20220177897A1 (en) Transcriptional relay system
Wouters et al. Assessing GPCR dimerization in living cells: Comparison of the NanoBiT assay with related bioluminescence-and fluorescence-based approaches
Alonso-Gardón et al. Split-Tobacco Etch Virus (Split-TEV) Method in G Protein-Coupled Receptor Interacting Proteins
US20220244253A1 (en) Systems and methods for measuring cell signaling protein activity
US20240132934A1 (en) Systems and methods for measuring cell signaling protein activity
Hasan et al. Overexpressed Gα13 activates serum response factor through stoichiometric imbalance with Gβγ and mislocalization to the cytoplasm
KR20150132222A (ko) 브로모도메인 억제 화합물을 식별하기 위한 융합 단백질 및 방법
JP2008228627A (ja) アリルハイドロカーボン受容体キメラタンパク質、それをコードする遺伝子、発現ベクター、形質転換細胞、および被験物質の毒性検出方法
Donaldson et al. Nuclear trafficking of the POZ-ZF protein Znf131
WO2003058197A2 (en) Detection of molecular interactions by beta-lactamase reporter fragment complementation
Kostova Functional characterization of a novel p97: ASPL protein complex
KR20230023218A (ko) N-말단의 일부가 절단된 ATF6β 단백질을 이용한 소포체 스트레스 조절 물질 스크리닝 방법
Hosseinpour et al. Overexpression of the Rho-guanine nucleotide exchange factor ECT2 inhibits nuclear translocation of nuclear receptor CAR in the mouse liver

Legal Events

Date Code Title Description
AS Assignment

Owner name: OCTANT, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CHAN, HENRY;CHAN, LEON YEN-LEE;COOPER, AARON ROSS;REEL/FRAME:058138/0117

Effective date: 20211110

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION